EV71 vaccine + influenza vaccine

This entry refers to the co-administration regimen of two distinct vaccines developed by subsidiaries of the **China National Biotec Group (CNBG)**. The regimen includes an **inactivated enterovirus 71 (EV71) vaccine** (produced by the Wuhan Institute of Biological Products) and a **trivalent split-virion inactivated influenza vaccine (IIV3)** (produced by the Changchun Institute of Biological Products). The EV71 vaccine is derived from the AHFY087VP5 strain (genotype C4) and is intended to prevent hand, foot, and mouth disease (HFMD). The IIV3 component contains hemagglutinin antigens from influenza A/H1N1, A/H3N2, and B/Victoria lineage strains. A Phase 4 clinical trial (NCT04554108) demonstrated that simultaneous administration of these vaccines in infants aged 6-11 months is safe and maintains the immunogenicity of both components, facilitating integrated immunization schedules.

Other names

EV71 vaccine and influenza vaccine co-administrationEV-71 vaccine and influenza vaccine co-administrationEV 71 vaccine and influenza vaccine co-administrationSimultaneous administration of EV71 and IIV3coadministration of EV71 vaccine and trivalent split-virion inactivated influenza vaccine